The Impact of an Antimicrobial Utilization Program on Antimicrobial Use
Information source: Washington University School of Medicine
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Antimicrobial Prescribing Practices
Intervention: Academic Detailing by the Antimicrobial Utilization Team (AUT) (Behavioral)
Phase: N/A
Status: Completed
Sponsored by: Washington University School of Medicine Official(s) and/or principal investigator(s):
Mark D King, MD, MSCR, Principal Investigator, Affiliation: Emory University
Summary
Multidisciplinary antimicrobial utilization teams (AUT) have been proposed as an effective
mechanism for improving antimicrobial use, but data on their efficacy remain limited. The
researchers postulated that a multi-disciplinary AUT would improve antimicrobial use in a
teaching hospital when compared to the standard of care (no AUT intervention).
Design: Randomized-controlled intervention trial. Setting: A 953-bed urban teaching
hospital.
Patients: Patients admitted to internal medicine ward teams who were prescribed selected
antimicrobial agents (piperacillin-tazobactam, levofloxacin, or vancomycin) during the
10month study period.
Intervention: Eight internal medicine ward teams were randomized monthly to academic
detailing by the AUT while 8 internal medicine ward teams were randomized indication-based
prescription of broad spectrum antimicrobials.
Measurements: Proportion of appropriate empiric, definitive, and end antimicrobial usage
(antimicrobial use from the initiation of therapy until definitive therapy is prescribed).
Clinical Details
Official title: The Impact of an Antimicrobial Utilization Program on Antimicrobial Use in a Large Public Hospital: A Randomized Controlled Trial
Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)
Primary outcome: Proportion of Appropriateness of Antimicrobial Prescriptions in each group.
Secondary outcome: Clinical Cure Rate, Mortality Rate between the two groups
Detailed description:
This study was conducted when Bernard C Camins, MD (BCC), one of the investigators, was
still employed at Emory University. The principal investigator is no longer at Emory
University. This trial is being registered by one of the investigators, BCC, so we can
submit the manuscript for publication. BCC is now at Washington University and this study
was conducted while he was at Emory University.
Eligibility
Minimum age: 18 Years.
Maximum age: 85 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- All patients prescribed vancomycin, piperacillin-tazobactam, or levofloxacin during
the time period of the study.
Locations and Contacts
Grady Memorial Hospital, Atlanta, Georgia 30303, United States
Additional Information
Starting date: October 2002
Last updated: October 31, 2007
|
